RxDoctor Payments Data

Kenneth Macknet, MD

Dermatology · Smyrna, TNNPI 1922199306

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.7% of the total across 443 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.

$12,309in general payments, 2019–2025

Across 443 payments — averaging $27.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Pfizer$895
  • Janssen Scientific Affairs, LLC$881
  • Sanofi$845
  • plus $4K from 25 others
$4,000in research payments, 2019–2025

Across 2 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$4K

What the payments were for

  • Speaking & faculty fees$3503%
  • Food & beverage$11,41393%
  • Education$5464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,309 in reported general payments places this provider in the 80th percentile of 209 dermatology providers in Tennessee.

See all dermatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$360,559
Medicare patients
751
Services billed
6,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$344,661
Dupixent PenDupilumab52$193,228
Cosentyx Sensoready (2 Pens)Secukinumab13$188,780
Humira(Cf) PenAdalimumab11$76,538
Metronidazole39$3,263
Ketoconazole94$1,993
Fluorouracil32$1,800
Clobetasol Propionate41$1,310
Doxycycline Hyclate26$720
Triamcinolone Acetonide55$613
Clindamycin Phosphate12$415
Mupirocin52$381
Fluocinonide11$377
Minoxidil21$374
ValacyclovirValacyclovir Hcl15$368

Paid to pharmacies, not to this prescriber.

Other dermatology in Smyrna

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →